{"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}],"units":"Participants"}],"groups":[{"description":"Cycles repeat every 3 weeks until disease Progression, unacceptable toxicity, or withdrawal.\n\nDocetaxel: Docetaxel: 75 mg/m2 on Day 1 of each 21-day cycle","id":"OG000","title":"Docetaxel"},{"description":"Cycles repeat every 3 weeks until disease Progression, unacceptable toxicity, or withdrawal.\n\nDocetaxel: Docetaxel: 75 mg/m2 on Day 1 of each 21-day cycle\n\nRamucirumab DP: Ramucirumab (DP): 10 mg/kg IV on day 1 of each 21-day cycle","id":"OG001","title":"Docetaxel + Ramucirumab DP"},{"description":"Cycles repeat every 3 weeks until disease Progression, unacceptable toxicity, or withdrawal.\n\nDocetaxel: Docetaxel: 75 mg/m2 on Day 1 of each 21-day cycle\n\nIcrucumab: 12 mg/kg IV on day 1 and Day 8 of each 21-day cycle","id":"OG002","title":"Docetaxel + Icrucumab"}],"populationDescription":"Zero participants analyzed. Data not collected.","reportingStatus":"POSTED","timeFrame":"40 months","title":"PD: Change in Circulating Levels of Soluble Vascular Endothelial Growth Factor-2 (VEGFR-2)","type":"SECONDARY"}